Second generation BTK inhibitor highly effective as solo therapy in adult leukemia
Updated data on the first 134 chronic lymphocytic leukemia patients treated with single-agent acalabrutinib shows that the drug was well-tolerated in the majority of patients treated and responses were durable over time, ...
Dec 13, 2017
0
3